The Intellectual Property team advised Pharmakon Advisors on the IP due diligence around its investment funds' entry into a credit facility agreement with Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focused on precision medicines. The facility provides Precigen with up to $125 million in non-dilutive financing, including $100 million funded at closing and a second $25 million tranche available at the company's discretion through March 31, 2027, subject to certain conditions.
Precigen is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
The Goodwin team was led by Carl A. Morales, Kevin Grumberg, Maria C. Smith, and Przemyslaw "Peter" McEwan.
For more information on the deal, please read the press release.